4D MOLECULAR THERAPEUTICS IN's ticker is FDMT and the CUSIP is 35104E100. A total of 91 filers reported holding 4D MOLECULAR THERAPEUTICS IN in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $176 | -28.5% | 13,813 | +1.4% | 0.00% | – |
| Q2 2023 | $246 | -11.5% | 13,616 | -15.7% | 0.00% | – |
| Q1 2023 | $278 | -36.2% | 16,161 | -17.7% | 0.00% | -100.0% |
| Q4 2022 | $436 | -99.7% | 19,634 | -0.1% | 0.00% | – |
| Q3 2022 | $158,000 | +132.4% | 19,661 | +102.6% | 0.00% | – |
| Q2 2022 | $68,000 | -80.4% | 9,705 | -57.7% | 0.00% | – |
| Q1 2022 | $347,000 | +10.2% | 22,944 | +59.6% | 0.00% | – |
| Q4 2021 | $315,000 | +23.0% | 14,374 | +51.4% | 0.00% | – |
| Q3 2021 | $256,000 | +36.9% | 9,495 | +22.3% | 0.00% | – |
| Q2 2021 | $187,000 | +23.0% | 7,761 | +121.7% | 0.00% | – |
| Q1 2021 | $152,000 | – | 3,500 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BVF INC/IL | 4,007,413 | $89,004,643 | 3.76% |
| Opaleye Management Inc. | 330,000 | $7,329,300 | 2.55% |
| Deep Track Capital, LP | 2,656,901 | $59,009,771 | 2.48% |
| Eagle Health Investments LP | 437,911 | $9,726,003 | 2.24% |
| COMMODORE CAPITAL LP | 598,385 | $13,290 | 2.00% |
| Octagon Capital Advisors LP | 499,996 | $11,104,911 | 1.73% |
| Casdin Capital, LLC | 630,000 | $13,992,300 | 1.08% |
| Soleus Capital Management, L.P. | 254,700 | $5,656,887 | 0.81% |
| VIKING GLOBAL INVESTORS LP | 3,937,914 | $87,461,070 | 0.44% |
| Peloton Wealth Strategists | 37,000 | $822 | 0.40% |